GLP-1 Obesity Guide for Clinicians

A 2026 clinician-oriented guide describes practical use of GLP-1 and dual GIP/GLP-1 receptor agonists for obesity. It is a journal article and practical guideline, not a new randomized trial. The abstract offers a care framework covering eligibility, baseline assessment, gradual dose escalation, adverse-effect management and long-term follow-up^[1]. Its value lies in organizing clinical work. It does not provide a new head-to-head estimate for semaglutide versus tirzepatide.

What kind of evidence this guide provides

PubMed classifies the paper as a journal article, while the authors describe it as a practical guideline for day-to-day prescribing. The abstract reports no enrolled cohort, random allocation or treatment comparison. Instead, it translates existing evidence and prescribing considerations into a sequence of decisions^[1]. That makes it a secondary clinical framework rather than a primary efficacy study.

This distinction sets the limit on the readout. The paper can help clinicians remember which questions belong before and after initiation, but the abstract cannot establish that one agent produces better outcomes for a particular patient. Comparative claims still require direct trials, current product labels and an assessment of whether the populations match the person being treated.

Eligibility starts with the indication

The guide begins with determining eligibility and completing a baseline evaluation^[1]. In the current US Wegovy label, weight reduction is indicated for adults with obesity, or adults with overweight plus at least one weight-related comorbid condition. The injection label also includes other indications with their own populations, including cardiovascular risk reduction and noncirrhotic MASH with moderate to advanced fibrosis^[2]. A shared drug name does not erase those indication-specific boundaries.

The US Zepbound label similarly includes long-term weight reduction for adults with obesity or overweight plus a weight-related condition. It also includes moderate to severe obstructive sleep apnea in adults with obesity^[3]. These are US labeling examples, not global rules. Approval wording, available presentations and reimbursement can differ by jurisdiction.

Baseline review is more than a BMI check

Both labels list contraindications for a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and prior serious hypersensitivity to the active ingredient or product excipients^[2][3]. A medication review also matters because both products can increase hypoglycemia risk when used with insulin or an insulin secretagogue. Their labels call for glucose monitoring in patients with diabetes and consideration of changes to the accompanying glucose-lowering treatment by the clinical team.

The practical review should also cover gastrointestinal symptoms, kidney risk during volume depletion, gallbladder disease, pancreatitis history, diabetic retinopathy and planned anesthesia. Both labels say the medicines are not recommended in severe gastroparesis. Both describe rare postmarketing pulmonary aspiration reports during procedures using general anesthesia or deep sedation, while noting that available data do not establish whether altered fasting or temporary discontinuation reduces that risk^[2][3].

Gradual escalation is a safety tool

The guide emphasizes gradual titration and management of commonly encountered side effects^[1]. Current US injection labels make that principle concrete. Wegovy uses four-week escalation intervals and allows a four-week delay when a step is not tolerated. Zepbound starts with a four-week initiation period, then permits increases only after at least four weeks on the current dose^[2][3]. These label schedules describe licensed products under clinician supervision. They are not a self-directed dosing protocol.

Gastrointestinal effects are central to that pacing. The labels for both medicines list nausea, diarrhea, vomiting and constipation among common reactions. They also warn that persistent gastrointestinal losses can lead to dehydration and acute kidney injury, making symptom severity and fluid status more important than simply reaching the next scheduled step^[2][3].

Semaglutide and tirzepatide are not interchangeable

The article's abstract says it summarizes practical differences between semaglutide and tirzepatide^[1]. Mechanism is one difference: Wegovy contains the GLP-1 receptor agonist semaglutide, while Zepbound contains tirzepatide, which acts at GIP and GLP-1 receptors. Their labeled indications, presentations, escalation schedules and maintenance options also differ^[2][3].

Neither label recommends combining its product with another medicine from the same pathway: Wegovy should not be used with another semaglutide-containing product or another GLP-1 receptor agonist, and Zepbound should not be used with another tirzepatide-containing product or a GLP-1 receptor agonist^[2][3]. For research and regulation background, see the semaglutide overview and our tirzepatide overview.

Follow-up should test benefit and burden

The guide frames obesity as chronic and frequently relapsing, then places long-term follow-up and maintenance after initiation rather than treating prescribing as the finish line^[1]. A useful follow-up therefore asks whether the agreed clinical goals are being met, whether adverse effects remain manageable, whether coexisting conditions or medicines have changed, and whether access makes continued treatment realistic.

Weight change alone does not answer every one of those questions. Glucose control, blood pressure, sleep-apnea care, liver disease and cardiovascular risk may each alter the reason for treatment and the monitoring plan. Conversely, a strong average result from an obesity trial cannot tell a clinician whether an individual will tolerate treatment or maintain access over time.

What we do not know from this paper

The accessible abstract does not describe how evidence was searched, graded or converted into recommendations. It does not report a consensus process, a new patient cohort or comparative outcome data. Full methodological detail may appear in the article, but it was not available through the indexed record reviewed for this draft. Recommendations that depend on a precise numerical threshold should therefore be checked against the full paper and the current local label before clinical use.

The evidence layers should remain separate. The 2026 guide supplies a practical sequence for clinician decisions. Product labels define approved uses, contraindications and warnings in a specific jurisdiction. Primary trials estimate outcomes in selected populations. None of those sources alone determines the right treatment for one person.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.